Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Nat Cancer. 2022 Dec 29;4(1):27–42. doi: 10.1038/s43018-022-00480-0

Extended Data Fig. 10 |. Effect of iScore on event free survival in AML.

Extended Data Fig. 10 |

a. Event free survival in high and low iScore Favorable risk patients in adult patients in the TCGA AML cohort (<60 yrs, n = 89). Log rank test was used to evaluate significance. b. Event free survival in pediatric patients in a microarray cohort (n = 372). Log rank test was used to evaluate significance. c. Event Free survival in high and low iScore favorable risk patients in the Alliance AML cohort (n = 323 < 60 years old). Log rank test was used to evaluate significance. d. Event free survival in high and low iScore intermediate risk patients in the Alliance AML cohort (n = 140 < 60 years old, n = 33 > =60 years old). Log rank test was used to evaluate significance. e. Event free survival in high and low iScore adverse risk patients in the Alliance AML cohort (n = 182 < 60 years old, n = 92 > =60 years old). Log rank test was used to evaluate significance.